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Edited by Sandro SonninoAbstract Long-chain unsaturated fatty acids, such as linoleic
acid, show antibacterial activity and are the key ingredients of
antimicrobial food additives and some antibacterial herbs. How-
ever, the precise mechanism for this antimicrobial activity re-
mains unclear. We found that linoleic acid inhibited bacterial
enoyl-acyl carrier protein reductase (FabI), an essential compo-
nent of bacterial fatty acid synthesis, which has served as a
promising target for antibacterial drugs. Additional unsaturated
fatty acids including palmitoleic acid, oleic acid, linolenic acid,
and arachidonic acid also exhibited the inhibition of FabI. How-
ever, neither the saturated form (stearic acid) nor the methyl es-
ter of linoleic acid inhibited FabI. These FabI-inhibitory
activities of various fatty acids and their derivatives very well
correlated with the inhibition of fatty acid biosynthesis using
[14C] acetate incorporation assay, and importantly, also corre-
lated with antibacterial activity. Furthermore, the supplementa-
tion with exogenous fatty acids reversed the antibacterial eﬀect
of linoleic acid, which showing that it target fatty acid synthesis.
Our data demonstrate for the ﬁrst time that the antibacterial ac-
tion of unsaturated fatty acids is mediated by the inhibition of
fatty acid synthesis.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The antibacterial activity of long-chain unsaturated fatty
acids have been well known for many years. Fatty acids func-
tion as the key ingredients of antimicrobial food additives
which inhibit the growth of unwanted microorganisms [1]. Lin-
oleic and oleic acids are antibacterial components in the herbs
(Helichrysum pedunculatum and Schotia brachypetala) used for
dressing wounds during male circumcision rituals in South
Africa [2,3]. Besides normal fatty acids, fatty acid derivatives
showing potent antimicrobial activities exist in nature. These
are mainly found in microorganisms, algae, or plants, which
may mediate chemical defense against microorganisms [4–6].*Corresponding author. Fax: +82 42 860 4595.
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doi:10.1016/j.febslet.2005.08.028Additionally, long-chain unsaturated fatty acids are bacterici-
dal to important pathogenic microorganisms, including Meth-
icillin-resistant Staphylococcus aureus [7–9], Helicobacter pylori
[10,11], and Mycobacteria [12]. These antibacterial actions of
fatty acids are usually attributed to long-chain unsaturated
fatty acids including oleic acid, linoleic acid, and linolenic acid,
while long-chain saturated fatty acids, including palmitic acid
and stearic acid, are less active [7,9,10,12]. However, their pri-
mary molecular target still remains unknown.
Fatty acid synthesis (FAS) in bacteria is essential to the pro-
duction of a number of lipid-containing components, including
the cell membranes [13]. Bacterial fatty acid synthesis is carried
out by a set of individual enzymes which are collectively
known as type II, while mammalian fatty acid is mediated
by a single multifunctional enzyme-acyl carrier protein
(ACP) complex referred to as type I. FabI is an enoyl-ACP
reductase which catalyzes the ﬁnal and rate-limiting step of
the chain elongation process of the type II FAS. Since there
is a lack of an overall sequence homolog with the correspond-
ing one of humans, FabI has been identiﬁed as a target for
antibacterial drug development [14]. Indeed, FabI has been re-
vealed as a target of the broad spectrum biocide, triclosan,
which is used as an antibacterial additive in a wide range of
consumer goods and was widely thought to be a non-speciﬁc
biocide which attacks bacterial membranes [15,16]. The site
of action of isoniazid, used in the treatment of tuberculosis
for 50 years, was also determined to be the mycobacterial FabI
homolog (termed InhA) [17].
During the course of our screening for FabI inhibitors from
natural resources for new antibacterial-drug development, we
frequently experienced the isolation of unsaturated fatty acids
as potent inhibitors of FabI. This led us to examine whether
unsaturated fatty acids are selective inhibitors of FabI and this
inhibition is related to the inhibition of fatty acid synthesis and
their antibacterial activity.2. Materials and methods
2.1. Materials
Oleic acid, linoleic acid, linolenic acid, stearic acid, palimitic acid,
palmitoleic acid, arachidonic acid, oleic acid methyl ester, linoleic acid
methyl ester, and arachidonic acid methyl ester were purchased from
Sigma. The unsaturated fatty acids are purchased all as the cis form.
[1-14C] acetate (57 lCi/lmol) and L-[U-14C] leucine (306 lCi/lmol)
were purchased from Amersham.blished by Elsevier B.V. All rights reserved.
Fig. 1. Inhibitory eﬀects of long-chain fatty acids on S. aureus FabI.
The values were represented as the means ± S.D. in triplicates obtained
from two independent experiments.
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(t-o-NAC-thioester)
To a solution of 2-octenoic acid (1138 mg, 8 mmol), N-acetylcyste-
amine (954 mg, 8 mmol), and 4-dimethylaminopyridine (2064 mg,
18.4 mmol) in dichloromethane at room temperature was added N-
(3-dimethylaminopropyl)-N 0-ethylcarbodiimide (3527 mg, 18.4 mmol).
After overnight the reaction solution was concentrated under vacuum,
and usual aqueous workup. The residue was puriﬁed by ﬂash chroma-
tography on silica gel (Hexane/EA = 3:1) to give the title compound
(1363 g, 70%) as a solid.
1H NMR (300 MHz, CDCl3) d 0.90 (t, J = 6.5 Hz, 3H), 1.26–1.33
(m, 4H), 1.45–1.50 (m, 2H), 1.97 (s, 3H), 2.20 (q, J = 7.2 Hz, 2H),
3.09 (t, J = 6.2 Hz, 2H), 3.46 (q, J = 6.2 Hz, 2H), 6.03 (br s, 1H),
6.07–6.15 (m, 1H), 6.89–6.99 (m, 1H).
2.3. Cloning of the fabI gene
The full length the fabI gene was ampliﬁed from genomic DNA
obtained from Escherichia coli or S. aureus (ATCC 26695). After
conﬁrming the DNA sequence, the gene was cloned into a mod-
iﬁed pET21b vector (Novagen, USA) which has 6 His-tag coding
regions at the N-terminus of the insert. After transforming the li-
gated mixture into BL21(DE3) with ampicillin resistance, the
resultant colonies were screened for their ability to overexpress
proteins of the correct size after induction by IPTG. To obtain
FabI, the bacteria were cultured in Luria–Broth media and in-
duced by 0.5 mM IPTG at 18 C for 18 h. The cells were collected
by centrifugation, resuspended in a buﬀer A (50 mM Tris(pH
8.0) + 300 mM NaCl + 5 mM imidazole) and disrupted by micro-
ﬂudizer (Model M-110L, Microﬂuidics, USA). Soluble fraction
was applied onto a Ni-NTA (Hi-trap, 5 ml, Amersham) and
washed by buﬀer A, followed by elution in buﬀer A containing
500 mM imidazole. The fusion protein was further puriﬁed by
Superdex 200 (Amersham) in a buﬀer B (50 mM Tris (pH
8.5) + 200 mM NaCl + 2 mM DTT), and the puriﬁed protein was
stored at 20 C until use.
2.4. FabI assay
Assays were carried out in half-area, 96-well microtitre plates.
Compounds were evaluated in 100 ll assay mixtures containing
components speciﬁc for each enzyme (see below). Reduction of
the t-o-NAC substrate analog was measured spectrophotometri-
cally by following the utilization of NADH or NADPH at
340 nm at 30 C for the linear period of the assay. S. aureus FabI
assays contained 50 mM sodium acetate, pH 6.5, 400 lM t-o-
NAC, 200 lM NADPH, and 150 nM S. aureus FabI. The rate
of decrease in the amount of NADPH in each reaction well
was measured by a microtiter ELISA reader using SOFTmax
PRO software (Molecular Devices, California, USA). The inhibi-
tory activity was calculated by the following formula: % of inhi-
bition = 100 · [1  (rate in the presence of compound/rate in the
untreated control)]. IC50 values were calculated by ﬁtting the data
to a sigmoid equation. An equal volume of dimethyl sulfoxide sol-
vent was used for the untreated control. E. coli FabI assays con-
tained 50 mM sodium phosphate, pH 7.5, 200 lM t-o-NAC,
200 lM NADH, and 150 nM E. coli FabI. The inhibitory activity
was determined in the same methods as for S. aureus FabI, as
described above.
2.5. Determination of MIC
The antibacterial activities of the test compounds were evaluated
using clinically isolated bacterial strains (Hoechst, Germany). The
strains were inoculated into 3 ml of Fleisch extract broth (Beef extract
1%, peptone 1%, NaCl 0.3%, Na2HPO4 Æ 12 H2O 0.2%, pH 7.4–7.5.
For Streptococcus pyogenes, 10% horse serum was supplemented.)
and cultured on a shaking incubator at 37 C for 18 h. Test compounds
were serially diluted in 2-fold dilutions from 2 mM to 15 lM. The
1.5 ml volume of each diluted solution was mixed with 13.5 ml of Mul-
ler Hinton agar (Difco, USA) and plated. The overnight-cultured
strains were 100-fold diluted with broth on a 96-well plate. The diluted
bacterial culture media were then inoculated (104 CFU/spot) on the
prepared agar plates by an automatic inoculator (Dynatech, USA).
The plates were incubated at 37 C for 18 h. The lowest concentration
that prevented the growth of each bacterium was determined to be
MIC.2.6. [1-14C]acetate incorporation
S. aureus was grown to mid-log phase in LB medium. Each 1 ml cul-
ture was treated with drugs for 10 min. An equal volume of DMSO
solvent was added to the untreated control. 2 lCi of [1-14C] acetate
was then added to the cultures and incubated at 37 C for 1 h in a sha-
ker. After being harvested by centrifugation, the cell pellets were
washed twice with PBS buﬀer. The total cellular lipids were then ex-
tracted with chloroform–methanol–water. The incorporated radioac-
tivity in the chloroform phase was measured by scintillation
counting. Data were expressed as percentage inhibition of incorpora-
tion compared with the untreated control.
2.7. L-[U-14C]leucine incorporation
S. aureus were prepared in the same manner as [1-14C]acetate incor-
poration. Each 1 ml culture was treated with drugs and an equal vol-
ume of DMSO solvent as the untreated control for 10 min. 0.6 lCi
of L-[U-14C] leucine was then added to the cultures and incubated at
37 C for 1 h in a shaker. The incorporation was terminated by the
addition of 10% (wt/vol) trichloroacetic acid (TCA) and cooling on
ice for 20 min. The precipitated material was collected on Whatman
GF/C glass microﬁber ﬁlters, washed with TCA and ethanol, dried,
and counted in a scintillation counter.
2.8. Supplementation of exogenous fatty acids
S. aureus was grown to mid-log phase in LB medium and diluted
1000-fold in the same medium. An 100 ll of the diluted cell suspension
(2 · 105 cells) were used to inoculate to each well of a 96-microtiter
plate containing 95 ll of LB media with inhibitors at the concentration
of MIC. 5 ll of the serially diluted fatty acid solution was supple-
mented, and the cell suspension was incubated at 37 C for 18 h. The
bacterial growth was determined by measuring at 650 nm using a
microtiter ELISA reader. Since fatty acids are easily transported into
cells from the medium as an ethanolic suspension [18], the fatty acids
were added as ethanolic solutions. An equal volume of ethanol solvent
was added for the untreated control.3. Results
3.1. Inhibition of FabI by linoleic acid
The ability of linoleic acid to speciﬁcally inhibit FabI was
investigated in an in vitro spectrophotometric assay using S.
aureus FabI and the enoyl-ACP substrate analog, t-o-NAC-
thioester. As shown in Fig. 1, the addition of increasing con-
centrations of linoleic acid to the reaction potently inhibited
the reduction of t-o-NAC-thioester by NDAPH with an IC50
of 39 lM. We expanded our analysis to include 4 additional
unsaturated fatty acids, palmitoleic acid, oleic acid, linolenic
acid, and arachidonic acid, to investigate whether the inhibi-
tion of FabI was a characteristic of this class of antibacterial
compound. All of the tested unsaturated fatty acids exhibited
inhibition of S. aureus FabI with IC50s between 25 and
Table 1
Comparison of eﬀects of long-chain fatty acids and their derivatives on enoyl reductase, bacterial viability, and [14C] acetate incorporation
Compounds IC50 (mM) MIC (mM) [
14C]acetate incorporation
S. aureus FabI S. aureus S. pyogenes
inhibition in S. aureus (IC50 (mM))
Palmitic acid (C16:0) >2 >2 >2 >2
Stearic acid (C18:0) >2 >2 >2 >2
Palmitoleic acid (C16:l) 0.041 0.4 0.1 0.028
Oleicacid (C18:l) 0.020 0.4 0.1 0.027
Linoleic acid (C18:2) 0.035 0.2 0.05 0.011
Linolenic acid (C18:3) 0.080 0.4 0.1 0.029
Arachidonic acid (C20:4) 0.041 0.2 0.1 0.030
Oleic add, Me ester >2 >2 >2 >2
Linoleic acid, Me ester >2 >2 >2 >2
Arachidonic acid, Me ester >2 NT NT >2
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saturated fatty acid forms and methyl ester forms of the unsat-
urated fatty acids were assayed. Interestingly, even at 2 mM,
saturated fatty acids, stearic acid and palmitic acid, did not in-
hibit FabI activity. Methyl ester forms of oleic acid, linoleic
acid, and arachidonic acid were also not active (Table 1). Thus,
these data clearly show that unsaturated fatty acids were solely
active and, importantly, both the double bond and carboxylic
acid moiety of the unsaturated fatty acids are critical for their
activity. For a double check of the fatty acid inhibition of
FabI, assays were carried out using E. coli FabI and resulted
in a very similar phenomena as in the case of S. aureus FabI
(data not shown).3.2. Mode of inhibition of FabI by linoleic acid
The kinetic mechanism for inhibition of FabI was investi-
gated using linoleic acid as a model compound. The FabI reac-
tion mechanism is obligatory ordered sequential with the
nucleotide cofactors, NADH or NADPH, as the ﬁrst sub-
strates. In order to determine whether linoleic acid binds to
the free enzyme, the enzyme–substrate complex, or both, the
inhibition pattern with respect to the substrate and the cofac-
tor was examined with a Lineweaver–Burk plot. The inhibition
of S. aureus FabI by linoleic acid was mixed with respect to t-
o-NAC with a Ki value of 14.6 lM (Fig. 2A and C). Addition-
ally, linoleic acid exhibited mixed inhibition respective to
NADPH (Fig. 2B). Thus, linoleic acid binds to the free enzyme
to prevent the binding of the nucleotide cofactor, and also
binds to the FabI–NADPH complex to prevent the binding
of the substrate.Fig. 2. The mechanism of inhibition of S. aureus FabI by linoleic acid
respective to t-o-NAC thioester (A) and NADPH (B), and Ki
determination of linoleic acid (C). (A, B) The reciprocals of the initial
reaction and substrate (A) and cofactor (B) concentrations are plotted.
(C) The slope values of the lines from graph A are plotted versus the
inhibitor concentrations aﬀording a line obtained by linear regression.
The intercept point of this line with the x-axis gives an approximate Ki
value of 14.6 lM for linoleic acid. The values were represented as the
means ± S.D. in triplicates.3.3. Antibacterial activities of fatty acids
Fatty acids tested in enzyme assays were tested for their anti-
bacterial activity against the Gram positive pathogens,S. aur-
eus and S. pyogenes, and against Gram negative bacteria,
including E. coli and Pseudomonas aeruginosa (Table 2). The
antibacterial activity of fatty acids tested in enzyme assays
was monitored by the ability (MIC) of the fatty acids to inhibit
cell growth. Unsaturated fatty acids tested exhibited the anti-
bacterial activity with MIC values of 0.05–0.4 mM against
Gram positive bacteria of S. aureus and S. pyogenes, while they
did not show antibacterial activity on Gram negative bacteria
of E. coli and P. aeruginosa. The MIC values are similar to the
reported values (0.05–0.5 mM) [9]. The saturated fatty acids
tested were not active on either Gram positive or Gram nega-
tive bacteria, even at 2 mM. This diﬀerential antibacterial
Fig. 3. Eﬀects of linoleic acid on fatty acid biosynthesis (A) and protein biosynthesis (B) of S. aureus. Triclosan (a known FabI inhibitor) and
chloramphenicol (a known protein synthesis inhibitor) were used as positive and negative controls, respectively. The values were represented as the
means ± S.D. in duplicates obtained from two independent experiments.
Table 2
Antibacterial eﬀects of long-chain fatty acids and their derivativesa
1 2 3 4 5 6 7 8 9
S. pyogenes 308A >1 >1 0.1 0.1 0.05 0.1 0.1 >1 >1
S. pyogenes 77A >1 >1 0.1 0.2 0.1 0.2 0.1 >1 >1
S. aureus SG5 11 >1 >1 0.4 0.4 0.4 0.4 0.2 >1 >1
S. aureus 285 >1 >1 0.4 0.4 0.2 0.4 0.2 >1 >1
S. aureus 503 >1 >1 0.4 0.4 0.2 0.4 0.2 >1 >1
E. coli 078 >1 >1 >1 >1 >1 >1 >1 >1 >1
E. coli DCO >1 >1 >1 >1 >1 >1 >1 >1 >1
P. aeruginosa 9027 >1 >1 >1 >1 >1 >1 >1 >1 >1
P. aeruginosa 1592E >1 >1 >1 >1 >1 >1 >1 >1 >1
1, Palmitic acid; 2, stearic acid; 3, palmitoleic acid; 4, oleic acid; 5, linoleic acid; 6, linolenic acid; 7, arachidonic acid; 8, oleic acid methyl ester; 9,
linoleic acid methyl ester.
aResults are given in mM.
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acids on Gram positive bacteria of S. aureus and S. pyogenes
was well correlated with the inhibition of S. aureus FabI
in vitro (Table 1).
3.4. Inhibition of cellular fatty acid synthesis by linoleic acid
To evaluate whether unsaturated fatty acids inhibit cellular
fatty acid synthesis, we determined whether the compounds
inhibited the incorporation of acetate into membrane fatty
acids in vivo. We measured the eﬀects of fatty acids on the
incorporation of [1-14C] acetate into the membrane fatty
acids in S. aureus. In agreement with their antibacterial activ-
ity, unsaturated fatty acids indeed blocked fatty acid synthe-
sis in vivo compared to the untreated cells, while saturated
fatty acid and esters of fatty acid did not aﬀect fatty acid syn-
thesis (Table 1). As shown in Fig. 3A, with an IC50 value of
10.9 lM, linoleic acid selectively inhibited incorporation of
radioactively labeled acetate into chloroform/methanol-
extractable phospholipids in a dose-dependent fashion, as
the known FabI inhibitor, triclosan, inhibited acetate incor-
poration. The potency of unsaturated acid tested in the inhi-
bition of [1-14C] acetate incorporation was similar to that
against FabI. In contrast, the incorporation of leucine into
proteins was not inhibited by linoleic acid at the concentra-
tions showing the inhibition of fatty acid synthesis, whereas
the protein synthesis inhibitor, chloramphenicol, inhibited
incorporation (Fig. 3B).3.5. Reversion of the antibacterial eﬀect of linoleic acid by the
supplementation with exogenous fatty acids
To see whether the antibacterial eﬀect of linoleic acid is due
to the inhibition of fatty acid synthesis, we examined whether
S. aureus in linoleic acid medium could grow by the supple-
mentation with exogenous fatty acids. S. aureus in medium
containing linoleic acid at the MIC value of 200 lM did not
grow at all compared to the untreated control cells. However,
when either saturated fatty acids (stearic acid and palimitic
acid) or unsaturated fatty acid (oleic acid) at sub-antibacterial
concentration were supplemented to the ﬁnal concentration of
50, 100, and 200 lM, the S. aureus cells in linoleic acid medium
grew well in a dose-dependent manner (Fig. 4A). Similarly, S.
aureus cells were rescued from the growth-inhibitory eﬀect of
triclosan, a FabI inhibitor, by addition of the exogenous fatty
acids (Fig. 4B). As a negative control, S. aureus in medium
containing chloramphenicol, a protein synthesis inhibitor,
did not grow in supplementation of the same fatty acids
(Fig. 4C). This result indicated that unsaturated fatty acids tar-
get fatty acid synthesis.4. Discussion
The antibacterial activity of long-chain unsaturated fatty
acids (C16–C20) against Staphylococci, Streptococci,Mycobac-
teria, Helicobacter, and Bacilli are well documented as the
Fig. 4. Growth of S. aureus in linoleic acid medium by supplemen-
tations with exogenous fatty acids (A). Triclosan (B) and chloram-
phenicol (C) were used as positive and negative controls, respectively.
The values were represented as the means ± S.D. in triplicates obtained
from two independent experiments.
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ents of traditional antibacterial and antituberculosis herbs,
antimicrobial components of milk fat eﬀective for stomach ul-
cers, and antibacterial compounds in plants or microorganisms
[1–3,7–12]. Even though there have been several reports
regarding the mode of action of long-chain unsaturated fatty
acids, the precise mechanism for this antimicrobial activity re-
mains unclear. Fatty acid synthesis in bacteria is essential to
the production of a number of lipid-containing components,
including the cell membranes. The bacterial fatty acid synthesis
is carried out by a set of individual enzymes in conjunction
with acyl carrier protein (ACP)-associated substrates. FabIcatalyzes the ﬁnal, rate-limiting step of the chain elongation
process in bacterial fatty acid synthesis; it has been validated
as an excellent target for antibacterial drug development
[13,14].
In this study, we found that linoleic acid is a model com-
pound of unsaturated fatty acids which selectively inhibits
FabI of S. aureus and E. coli. Other long-chain unsaturated
fatty acids also inhibit FabI, whereas long-chain saturated
fatty acids were not active. Methyl esteriﬁcation of long-chain
unsaturated fatty acids results in the loss of FabI-inhibitory
activity. In the antibacterial assay using whole cells, unsatu-
rated fatty acids showed greater inhibition than saturated fatty
acids, which is consistent with the results seen by several other
investigators [1,19]. Methyl ester derivatives were less active
than the corresponding acids. This is consistent with the obser-
vations of Kabara et al. [9], who showed that the free carbonyl
group is necessary for activity. It is important to note that the
diﬀerential action of these fatty acids and their derivatives in
the FabI enzyme assay is highly signiﬁcantly correlated with
that in their antibacterial activity against the Gram positive
bacteria, strongly suggesting that the FabI step in bacterial
type II fatty acid synthesis could be a molecular target for
long-chain unsaturated fatty acids. This hypothesis was sup-
ported by the incorporation assay of [1-14C] acetate into mem-
brane fatty acids in bacterial cells, showing that long-chain
unsaturated fatty acids inhibit fatty acid synthesis, while their
methyl esters and saturated fatty acids do not. Importantly,
antibacterial eﬀect of linoleic acid was reversed by the supple-
mentation with either saturated fatty acids (stearic acid and
palimitic acid) without antibacterial activity or unsaturated
fatty acid (oleic acid) at sub-antibacterial concentration. This
result indicated that unsaturated fatty acids exerted their anti-
bacterial eﬀect by inhibiting fatty acid synthesis.
Greenway and Dyke [19] had suggested that linoleic acid
probably inhibited growth by increasing the permeability of
the bacterial membrane as a result of its surfactant action. This
hypothesis had not explained the reason why saturated fatty
acids did not inhibit bacterial growth. However, this question
could be answered by our ﬁndings that there were the diﬀer-
ences between unsaturated fatty acids and saturated fatty acids
in terms of the inhibition of fatty acid synthesis and FabI.
Unsaturated fatty acids also inhibit E. coli FabI at a similar
dosage as with S. aureus. However, this is not correlated with a
lack of, or very weak, antibacterial activity of unsaturated
fatty acids against E. coli. Long-chain unsaturated fatty acids,
including linoleic acid, are well known to not inhibit Gram
negative bacteria such as E. coli [1,2,9,10]. This large diﬀerence
in the fatty acid sensitivities between Gram positive and Gram
negative bacteria may result from the impermeability of the
outer membrane of Gram negative bacteria since the outer
membrane of Gram negative bacteria is an eﬀective barrier
against hydrophobic substances [20–22].
Unsaturated fatty acids have been known to reduce tumor
growth, but their molecular mechanism has remained elusive
[23–25]. Type I fatty acid synthase (FAS I), by which the de
novo synthesis of fatty acids in mammalian cells is accom-
plished, is overexpressed in some breast cancer cells; inhibition
of FAS I has been shown to induce apotosis in breast cancer
cells, and, consequently, is a potential chemotherapeutic target
[26,27]. Triclosan, a well-known inhibitor of FabI, has been
shown to be toxic to breast cancer cells [28]. Since fatty acids
selectively inhibit fatty acid synthesis, the anticancer activity
5162 C.J. Zheng et al. / FEBS Letters 579 (2005) 5157–5162of fatty acids can be speculated to arise from the inhibition of
fatty acid synthesis.
In summary, long-chain unsaturated fatty acids are selective
inhibitors of FabI and antibacterial eﬀect of long-chain unsat-
urated fatty acids is due to their inhibition of fatty acid biosyn-
thesis. Also, the diﬀerential activity was found between
unsaturated fatty acids and saturated fatty acids in the inhibi-
tion of fatty acid synthesis and FabI, which could explain the
unsolved question why saturated fatty acids did not have anti-
bacterial activity.
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